<drug type="small molecule" created="2016-10-20" updated="2017-03-23">
  <drugbank-id primary="true">DB12598</drugbank-id>
  <name>Nafamostat</name>
  <description>Nafamostat has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome.</description>
  <cas-number>81525-10-2</cas-number>
  <unii>Y25LQ0H97D</unii>
  <average-mass>347.378</average-mass>
  <monoisotopic-mass>347.138224807</monoisotopic-mass>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as guanidinobenzoic acids and derivatives. These are aromatic compounds containing a guanidine group linked to the benzene ring of a benzoic acid (or a derivative thereof).</description>
    <direct-parent>Guanidinobenzoic acids and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Benzoic acids and derivatives</subclass>
    <alternative-parent>Benzoic acid esters</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carboxamidines</alternative-parent>
    <alternative-parent>Carboximidamides</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Guanidines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Naphthalenes</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <substituent>Amidine</substituent>
    <substituent>Aromatic homopolycyclic compound</substituent>
    <substituent>Benzoate ester</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Carboximidamide</substituent>
    <substituent>Carboxylic acid amidine</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Guanidine</substituent>
    <substituent>Guanidinobenzoic acid or derivatives</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Naphthalene</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amidines</category>
      <mesh-id>D000578</mesh-id>
    </category>
    <category>
      <category>Analgesics</category>
      <mesh-id>D000700</mesh-id>
    </category>
    <category>
      <category>Analgesics, Non-Narcotic</category>
      <mesh-id>D018712</mesh-id>
    </category>
    <category>
      <category>Anti-Inflammatory Agents</category>
      <mesh-id>D000893</mesh-id>
    </category>
    <category>
      <category>Anti-Inflammatory Agents, Non-Steroidal</category>
      <mesh-id>D000894</mesh-id>
    </category>
    <category>
      <category>Anticoagulants</category>
      <mesh-id>D000925</mesh-id>
    </category>
    <category>
      <category>Antirheumatic Agents</category>
      <mesh-id>D018501</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Complement Inactivating Agents</category>
      <mesh-id>D051056</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Fibrinolysin, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Immunosuppressive Agents</category>
      <mesh-id>D007166</mesh-id>
    </category>
    <category>
      <category>Kallikreins, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Organic Chemicals</category>
      <mesh-id>D009930</mesh-id>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Protease Inhibitors</category>
      <mesh-id>D011480</mesh-id>
    </category>
    <category>
      <category>Sensory System Agents</category>
      <mesh-id>D018689</mesh-id>
    </category>
    <category>
      <category>Serine Proteinase Inhibitors</category>
      <mesh-id>D015842</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
    <category>
      <category>Trypsin Inhibitors</category>
      <mesh-id>D014361</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB05107</drugbank-id>
      <name>16-Bromoepiandrosterone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with 16-Bromoepiandrosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01434</drugbank-id>
      <name>19-norandrostenedione</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with 19-norandrostenedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01536</drugbank-id>
      <name>4-Androstenedione</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with 4-Androstenedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01456</drugbank-id>
      <name>5-androstenedione</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with 5-androstenedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>The serum concentration of Abacavir can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Nafamostat may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Aceclofenac may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Nafamostat may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12618</drugbank-id>
      <name>Acetovanillone</name>
      <description>Acetovanillone may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11617</drugbank-id>
      <name>Aclarubicin</name>
      <description>Nafamostat may decrease the excretion rate of Aclarubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00210</drugbank-id>
      <name>Adapalene</name>
      <description>Adapalene may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Alclometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The serum concentration of Alfuzosin can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>Nafamostat may decrease the antihypertensive activities of Aliskiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Allylestrenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The serum concentration of Alprazolam can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>The therapeutic efficacy of Alprostadil can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>Alteplase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11372</drugbank-id>
      <name>Altrenogest</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Altrenogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>ALX-0081</name>
      <description>ALX-0081 may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Amcinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>Nafamostat may decrease the excretion rate of Amikacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>Nafamostat may decrease the antihypertensive activities of Amiloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The serum concentration of Amineptine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The serum concentration of Aminophylline can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>Aminosalicylic Acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06263</drugbank-id>
      <name>Amrubicin</name>
      <description>Nafamostat may decrease the excretion rate of Amrubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Nafamostat may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12081</drugbank-id>
      <name>Anecortave</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Anecortave.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>Anisodamine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>Anistreplase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>annamycin</name>
      <description>Nafamostat may decrease the excretion rate of annamycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>Antipyrine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Nafamostat may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>AOP200704</name>
      <description>Nafamostat may decrease the antihypertensive activities of Aop200704.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Apixaban may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>Nafamostat may decrease the excretion rate of Apramycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>Apremilast may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>Nafamostat may decrease the excretion rate of Arbekacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Nafamostat may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Nafamostat may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>Astaxanthin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The serum concentration of Atorvastatin can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>Azapropazone may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Nafamostat may increase the nephrotoxic activities of Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09005</drugbank-id>
      <name>Batroxobin</name>
      <description>Batroxobin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06401</drugbank-id>
      <name>Bazedoxifene</name>
      <description>Bazedoxifene may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG</name>
      <description>The therapeutic efficacy of Bcg can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Nafamostat may increase the anticoagulant activities of Becaplermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11897</drugbank-id>
      <name>Beclomethasone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Beclomethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Befunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>Bemiparin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of adverse effects can be increased when Benazepril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>Benoxaprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The therapeutic efficacy of Beraprost can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>Betulinic Acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00905</drugbank-id>
      <name>Bimatoprost</name>
      <description>The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Nafamostat may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Nafamostat can be decreased when it is combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00963</drugbank-id>
      <name>Bromfenac</name>
      <description>Bromfenac may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Bromocriptine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12160</drugbank-id>
      <name>Bucillamine</name>
      <description>Bucillamine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Nafamostat may decrease the diuretic activities of Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Cabergoline can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan</name>
      <description>The risk or severity of adverse effects can be increased when Candesartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>The risk or severity of adverse effects can be increased when Candoxatril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Cangrelor may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of adverse effects can be increased when Captopril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The metabolism of Nafamostat can be increased when combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00429</drugbank-id>
      <name>Carboprost Tromethamine</name>
      <description>The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00521</drugbank-id>
      <name>Carteolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Carteolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>Castanospermine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Nafamostat may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Chloroquine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>The serum concentration of Chlorotrianisene can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The risk or severity of adverse effects can be increased when Cilazapril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The serum concentration of Cisapride can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Nafamostat may increase the anticoagulant activities of Citric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasol propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Clocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00720</drugbank-id>
      <name>Clodronate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Clodronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The serum concentration of Clomipramine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>Clonixin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11507</drugbank-id>
      <name>Cloprostenol</name>
      <description>The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00930</drugbank-id>
      <name>Colesevelam</name>
      <description>Colesevelam can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>Colestipol can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11249</drugbank-id>
      <name>Collagenase</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Collagenase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated Equine Estrogens</name>
      <description>The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>Curcumin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The serum concentration of Cyclobenzaprine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Cyclosporine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08921</drugbank-id>
      <name>D-Limonene</name>
      <description>D-Limonene may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Nafamostat may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Nafamostat may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>Dasatinib may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>Nafamostat may decrease the excretion rate of Daunorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Defibrotide may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05804</drugbank-id>
      <name>dehydroepiandrosterone sulfate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with dehydroepiandrosterone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The serum concentration of Delavirdine can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Denosumab is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Deoxycholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>dersalazine</name>
      <description>dersalazine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The serum concentration of Desipramine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Nafamostat may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>Desmoteplase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Desogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Desoximetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06780</drugbank-id>
      <name>Desoxycorticosterone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Desoxycorticosterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01134</drugbank-id>
      <name>Desoxycorticosterone Pivalate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Desoxycorticosterone Pivalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Nafamostat may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11122</drugbank-id>
      <name>Dextran 40</name>
      <description>Nafamostat may increase the anticoagulant activities of Dextran 40.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11076</drugbank-id>
      <name>Dextran 70</name>
      <description>Nafamostat may increase the anticoagulant activities of Dextran 70.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11241</drugbank-id>
      <name>Dextran 75</name>
      <description>Nafamostat may increase the anticoagulant activities of Dextran 75.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of adverse effects can be increased when Diclofenac is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>Diclofenac may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Nafamostat may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00890</drugbank-id>
      <name>Dienestrol</name>
      <description>The serum concentration of Dienestrol can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Dienogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Diflorasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Difluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The serum concentration of Dihydroergotamine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>Nafamostat may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Diltiazem can be decreased when combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12789</drugbank-id>
      <name>Dinoprost</name>
      <description>The therapeutic efficacy of Dinoprost can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01160</drugbank-id>
      <name>Dinoprost Tromethamine</name>
      <description>The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00917</drugbank-id>
      <name>Dinoprostone</name>
      <description>The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>Ditazole may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The serum concentration of Dosulepin can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The serum concentration of Doxepin can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>Nafamostat may decrease the excretion rate of Doxorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Nafamostat may increase the hyperkalemic activities of Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>Drotrecogin alfa may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>Droxicam may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>Duvelisib may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00378</drugbank-id>
      <name>Dydrogesterone</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Dydrogesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The serum concentration of Dyphylline can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11687</drugbank-id>
      <name>E6201</name>
      <description>E6201 may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>Ebselen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Nafamostat may increase the anticoagulant activities of Edetic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Edoxaban may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of adverse effects can be increased when Enalapril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00109</drugbank-id>
      <name>Enfuvirtide</name>
      <description>The serum concentration of Enfuvirtide can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Enoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Nafamostat may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>Epinastine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>Epirizole may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>Nafamostat may decrease the excretion rate of Epirubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Nafamostat may decrease the antihypertensive activities of Eplerenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06392</drugbank-id>
      <name>eplivanserine</name>
      <description>eplivanserine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of adverse effects can be increased when Eprosartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03515</drugbank-id>
      <name>Equilenin</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Equilenin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02187</drugbank-id>
      <name>Equilin</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Equilin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The serum concentration of Ergoloid mesylate can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergonovine</name>
      <description>The serum concentration of Ergonovine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The serum concentration of Ergotamine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The serum concentration of Esmirtazapine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The serum concentration of Estramustine can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>Estriol may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Estrogens, esterified</name>
      <description>The serum concentration of Estrogens, esterified can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>Estrone may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The serum concentration of Estrone sulfate can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>Nafamostat may decrease the diuretic activities of Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>Etanercept may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinyl Estradiol</name>
      <description>The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Nafamostat may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Ethynodiol diacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01077</drugbank-id>
      <name>Etidronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Etidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>Etofenamate may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Etonogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The serum concentration of Etravirine can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Evening primrose oil may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06246</drugbank-id>
      <name>exisulind</name>
      <description>exisulind may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>Fenbufen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>Fenoprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11411</drugbank-id>
      <name>Fenprostalene</name>
      <description>The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08977</drugbank-id>
      <name>Fibrinolysin</name>
      <description>Fibrinolysin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Nafamostat may increase the immunosuppressive activities of Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Fleroxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of adverse effects can be increased when Floctafenine is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06250</drugbank-id>
      <name>fluasterone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with fluasterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Nafamostat may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Flumethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>Flunixin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone Acetonide</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocinolone Acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Fluorometholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11519</drugbank-id>
      <name>Fluprostenol</name>
      <description>The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Flurandrenolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>Flurbiprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone Propionate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone Propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic Acid</name>
      <description>The therapeutic efficacy of Folic Acid can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11728</drugbank-id>
      <name>Fondaparinux</name>
      <description>Nafamostat may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux sodium</name>
      <description>Nafamostat may increase the anticoagulant activities of Fondaparinux sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01342</drugbank-id>
      <name>Forasartan</name>
      <description>The risk or severity of adverse effects can be increased when Forasartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Formestane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>The risk or severity of adverse effects can be increased when Fosinopril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>Nafamostat may decrease the excretion rate of Framycetin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Nafamostat may decrease the diuretic activities of Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with G17DT.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Nafamostat may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10532</drugbank-id>
      <name>Garlic</name>
      <description>The serum concentration of Nafamostat can be decreased when it is combined with Garlic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Gatifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08964</drugbank-id>
      <name>Gemeprost</name>
      <description>The therapeutic efficacy of Gemeprost can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>Nafamostat may decrease the excretion rate of Geneticin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>Genistein may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>Nafamostat may decrease the excretion rate of Gentamicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>GENTAMICIN C1A</name>
      <description>Nafamostat may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Gestodene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Gestrinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with GI-5005.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05212</drugbank-id>
      <name>HE3286</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with HE3286.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03404</drugbank-id>
      <name>Hemin</name>
      <description>Hemin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Nafamostat may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>The serum concentration of Hexestrol can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>Higenamine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>HMPL-004</name>
      <description>HMPL-004 may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Nafamostat may decrease the antihypertensive activities of Hydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Hydroxyprogesterone caproate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>Nafamostat may decrease the excretion rate of Hygromycin B which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Ibandronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibrutinib is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>Ibuprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>Ibuproxam may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Icatibant may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>Nafamostat may decrease the excretion rate of Idarubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>idraparinux</name>
      <description>Nafamostat may increase the anticoagulant activities of idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The therapeutic efficacy of Iloprost can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The risk or severity of adverse effects can be increased when Imidapril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The therapeutic efficacy of Indapamide can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Indobufen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>Indomethacin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>Indoprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05322</drugbank-id>
      <name>INGN 201</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with INGN 201.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with INGN 225.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06013</drugbank-id>
      <name>INNO-206</name>
      <description>Nafamostat may decrease the excretion rate of INNO-206 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The risk or severity of adverse effects can be increased when Irbesartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>Isoxicam may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06157</drugbank-id>
      <name>Istaroxime</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Istaroxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>Nafamostat may decrease the excretion rate of Kanamycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12017</drugbank-id>
      <name>KCT-0809</name>
      <description>Kct 0809 may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>Kebuzone may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Ketoprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of adverse effects can be increased when Ketorolac is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>Ketorolac may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00654</drugbank-id>
      <name>Latanoprost</name>
      <description>The therapeutic efficacy of Latanoprost can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Nafamostat may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01210</drugbank-id>
      <name>Levobunolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Levobunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Levonorgestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>The risk or severity of adverse effects can be increased when Lisinopril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>Lisofylline may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium</name>
      <description>The serum concentration of Lithium can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Lomefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>Lornoxicam may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The risk or severity of adverse effects can be increased when Losartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The serum concentration of Lovastatin can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>Loxoprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11425</drugbank-id>
      <name>Luprostiol</name>
      <description>The therapeutic efficacy of Luprostiol can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Lynestrenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Magnesium salicylate may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00179</drugbank-id>
      <name>Masoprocol</name>
      <description>Masoprocol may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05402</drugbank-id>
      <name>ME-609</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with ME-609.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>Meclofenamic acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09124</drugbank-id>
      <name>Medrogestone</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Medrogestone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Medrysone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>Mefenamic acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>Meloxicam may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Nafamostat may increase the nephrotoxic activities of Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The serum concentration of Mestranol can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>Metamizole may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>The serum concentration of Methallenestril can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The serum concentration of Methotrexate can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01214</drugbank-id>
      <name>Metipranolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Metipranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The therapeutic efficacy of Metolazone can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01578</drugbank-id>
      <name>Metrizamide</name>
      <description>Nafamostat may decrease the excretion rate of Metrizamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The serum concentration of Midazolam can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The serum concentration of Mirtazapine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00929</drugbank-id>
      <name>Misoprostol</name>
      <description>The therapeutic efficacy of Misoprostol can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>Mizoribine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of adverse effects can be increased when Moexipril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of adverse effects can be increased when Morniflumate is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Mycophenolate mofetil may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Mycophenolic acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Nafamostat may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00735</drugbank-id>
      <name>Naftifine</name>
      <description>Naftifine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic Acid</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Nalidixic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Naproxen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05410</drugbank-id>
      <name>NCX 1022</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with NCX 1022.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05822</drugbank-id>
      <name>NCX 4016</name>
      <description>NCX 4016 may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>Nafamostat may decrease the excretion rate of Neamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Nefazodone can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>Nafamostat may decrease the excretion rate of Neomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06802</drugbank-id>
      <name>Nepafenac</name>
      <description>Nepafenac may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>Nafamostat may decrease the excretion rate of Netilmicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic Acid</name>
      <description>Niflumic Acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11636</drugbank-id>
      <name>Nomegestrol</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Nomegestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The serum concentration of Nortriptyline can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04870</drugbank-id>
      <name>Oleoyl estrone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Oleoyl estrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The risk or severity of adverse effects can be increased when Olmesartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>Olopatadine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Nafamostat may increase the nephrotoxic activities of Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04865</drugbank-id>
      <name>Omacetaxine mepesuccinate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Omacetaxine mepesuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The risk or severity of adverse effects can be increased when Omapatrilat is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11133</drugbank-id>
      <name>Omega-3 fatty acids</name>
      <description>Omega-3 fatty acids may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The serum concentration of Opipramol can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11444</drugbank-id>
      <name>Orgotein</name>
      <description>Orgotein may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Nafamostat may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>Oxaprozin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>Oxyphenbutazone may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Pamidronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>Parnaparin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>Nafamostat may decrease the excretion rate of Paromomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Pazufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Pefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Pentosan Polysulfate may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The risk or severity of adverse effects can be increased when Perindopril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Pethidine</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Pethidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Nafamostat may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Nafamostat may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>Phenylbutazone may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The serum concentration of Pimozide can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>Nafamostat may decrease the excretion rate of Pirarubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>Nafamostat may decrease the diuretic activities of Piretanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>Pirfenidone may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>Piroxicam may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Plasmin</name>
      <description>Plasmin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06810</drugbank-id>
      <name>Plicamycin</name>
      <description>Nafamostat may decrease the excretion rate of Plicamycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The therapeutic efficacy of Polythiazide can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The serum concentration of Pralatrexate can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01708</drugbank-id>
      <name>Prasterone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Prasterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Prasugrel may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Prednicarbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02789</drugbank-id>
      <name>Pregnenolone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Pregnenolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The serum concentration of Nafamostat can be increased when it is combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The therapeutic efficacy of Nafamostat can be decreased when used in combination with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Propacetamol may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02304</drugbank-id>
      <name>Prostaglandin B2</name>
      <description>The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08863</drugbank-id>
      <name>Prostaglandin D2</name>
      <description>The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03866</drugbank-id>
      <name>Prostaglandin G2</name>
      <description>The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11454</drugbank-id>
      <name>Prostalene</name>
      <description>The therapeutic efficacy of Prostalene can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Nafamostat may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Nafamostat may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Nafamostat may increase the anticoagulant activities of Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The serum concentration of Protriptyline can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Prulifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05173</drugbank-id>
      <name>PTC299</name>
      <description>PTC299 may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>Nafamostat may decrease the excretion rate of Puromycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The risk or severity of adverse effects can be increased when Quinapril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The therapeutic efficacy of Quinethazone can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies vaccine</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Rabies vaccine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies vaccine</name>
      <description>The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The risk or severity of adverse effects can be increased when Ramipril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The risk or severity of adverse effects can be increased when Rescinnamine is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>Reteplase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Nafamostat may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>Nafamostat may decrease the excretion rate of Ribostamycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Rimexolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with CDX-110.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The serum concentration of Riociguat can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Risedronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Nafamostat may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Roflumilast may increase the immunosuppressive activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Rosoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The serum concentration of Rosuvastatin can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>S Equol</name>
      <description>S Equol may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>The risk or severity of adverse effects can be increased when Sacubitril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>Salicylamide may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>Salsalate may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>The risk or severity of adverse effects can be increased when Saprisartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06763</drugbank-id>
      <name>Saralasin</name>
      <description>The risk or severity of adverse effects can be increased when Saralasin is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05692</drugbank-id>
      <name>SCH-530348</name>
      <description>SCH-530348 may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12179</drugbank-id>
      <name>Secoisolariciresinol</name>
      <description>Secoisolariciresinol may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>Selexipag may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>Seratrodast may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The serum concentration of Sildenafil can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Simeprevir can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06688</drugbank-id>
      <name>Sipuleucel-T</name>
      <description>The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>Nafamostat may decrease the excretion rate of Sisomicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04978</drugbank-id>
      <name>SP1049C</name>
      <description>Nafamostat may decrease the excretion rate of SP1049C which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00919</drugbank-id>
      <name>Spectinomycin</name>
      <description>Nafamostat may decrease the excretion rate of Spectinomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>The risk or severity of adverse effects can be increased when Spirapril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Nafamostat may decrease the antihypertensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with SRP 299.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>SRT501 may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of Nafamostat can be increased when combined with St. John&amp;#39;s Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>Streptokinase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>Nafamostat may decrease the excretion rate of Streptomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>Nafamostat may decrease the excretion rate of Streptozocin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06206</drugbank-id>
      <name>Sugammadex</name>
      <description>Sugammadex may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Nafamostat may increase the nephrotoxic activities of Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>Sulindac may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Nafamostat may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12708</drugbank-id>
      <name>Sulprostone</name>
      <description>The therapeutic efficacy of Sulprostone can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00870</drugbank-id>
      <name>Suprofen</name>
      <description>Suprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Tacrolimus is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The metabolism of Tacrolimus can be decreased when combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08819</drugbank-id>
      <name>Tafluprost</name>
      <description>The therapeutic efficacy of Tafluprost can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of adverse effects can be increased when Talniflumate is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01349</drugbank-id>
      <name>Tasosartan</name>
      <description>The risk or severity of adverse effects can be increased when Tasosartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09411</drugbank-id>
      <name>Technetium tc 99m etidronate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Technetium tc 99m etidronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09138</drugbank-id>
      <name>Technetium Tc-99m Medronate</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Technetium Tc-99m Medronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The risk or severity of adverse effects can be increased when Telmisartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The risk or severity of adverse effects can be increased when Temocapril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>Tenecteplase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Tenofovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>Tenoxicam may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>Tepoxalin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>Teriflunomide may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>Tesmilifene may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with TG4010.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The serum concentration of Theophylline can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The serum concentration of Tianeptine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Tiaprofenic acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>Ticagrelor may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Tiludronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Nafamostat may decrease the antihypertensive activities of Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>Tinoridine may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>Tinzaparin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The serum concentration of Nafamostat can be decreased when it is combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>Nafamostat may decrease the excretion rate of Tobramycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>Nafamostat may increase the immunosuppressive activities of Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic Acid</name>
      <description>Tolfenamic Acid may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>Tolmetin may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Nafamostat may decrease the diuretic activities of Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The risk or severity of adverse effects can be increased when Trandolapril is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the neutropenic activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00287</drugbank-id>
      <name>Travoprost</name>
      <description>The therapeutic efficacy of Travoprost can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of adverse effects can be increased when Treprostinil is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>Nafamostat may decrease the antihypertensive activities of Triamterene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The serum concentration of Triazolam can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Triflusal may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Trisalicylate-choline</name>
      <description>Trisalicylate-choline may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>Nafamostat may increase the neuroexcitatory activities of Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06826</drugbank-id>
      <name>Unoprostone</name>
      <description>The therapeutic efficacy of Unoprostone can be decreased when used in combination with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>Urokinase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Valdecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic Acid</name>
      <description>The serum concentration of Valproic Acid can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00385</drugbank-id>
      <name>Valrubicin</name>
      <description>Nafamostat may decrease the excretion rate of Valrubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The risk or severity of adverse effects can be increased when Valsartan is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>The serum concentration of Vancomycin can be increased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be decreased when combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00163</drugbank-id>
      <name>Vitamin E</name>
      <description>Vitamin E may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of adverse effects can be increased when Vorapaxar is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Nafamostat may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Nafamostat may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>YM150</name>
      <description>Nafamostat may increase the anticoagulant activities of Ym150.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>Zaltoprofen may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Zidovudine can be decreased when it is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>Zileuton may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Zoledronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>Zomepirac may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11618</drugbank-id>
      <name>Zorubicin</name>
      <description>Nafamostat may decrease the excretion rate of Zorubicin which could result in a higher serum level.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.91</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.41e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.52</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>6-carbamimidoylnaphthalen-2-yl 4-carbamimidamidobenzoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>6-carbamimidoylnaphthalen-2-yl 4-carbamimidamidobenzoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>347.378</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>347.138224807</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C19H17N5O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>MQQNFDZXWVTQEH-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>138.07</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>122.12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>37.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>11.32</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers/>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
